J Korean Med Sci.  2020 Nov;35(43):e388. 10.3346/jkms.2020.35.e388.

Impact of COVID-19 Pandemic on the National PPM Tuberculosis Control Project in Korea: the Korean PPM Monitoring Database between July 2019 and June 2020

• Min Js
• Kim HW
• Koo HK
• Ko Ys
• Oh JY
• Kim Jt
• Yang Jy
• Kwon Yh
• Park YJ
• Kang JY
• Lee SS
• Park JS
• Kim JS

• KMID: 2508503
• DOI: http://doi.org/10.3346/jkms.2020.35.e388

Abstract

Background
The coronavirus disease 2019 (COVID-19) pandemic caused disruptions to healthcare systems and endangered the control and prevention of tuberculosis (TB). We investigated the nationwide effects of COVID-19 on the national Public-Private Mix (PPM) TB control project in Korea, using monitoring indicators from the Korean PPM monitoring database.
Methods
The Korean PPM monitoring database includes data from patients registered at PPM hospitals throughout the country. Data of six monitoring indicators for active TB cases updated between July 2019 and June 2020 were collected. The data of each cohort throughout the country and in Daegu-Gyeongbuk, Seoul Metropolitan Area, and Jeonnam-Jeonbuk were collated to provide nationwide data. The data were compared using the χ 2 test for trend to evaluate quarterly trends of each monitoring indicator at the national level and in the prespecified regions.
Results
Test coverages of sputum smear (P = 0.622) and culture (P = 0.815), drug susceptibility test (P = 0.750), and adherence rate to initial standard treatment (P = 0.901) at the national level were not significantly different during the study period. The rate of loss to follow-up among TB cases at the national level was not significantly different (P = 0.088) however, the treatment success rate among the smear-positive drug-susceptible pulmonary TB cohort at the national level significantly decreased, from 90.6% to 84.1% (P < 0.001). Treatment success rate in the Seoul metropolitan area also significantly decreased during the study period, from 89.4% to 84.5% (P = 0.006).
Conclusion
Our study showed that initial TB management during the COVID-19 pandemic was properly administered under the PPM project in Korea. However, our study cannot confirm or conclude a decreased treatment success rate after the COVID-19 pandemic due to limited data.

Keyword

SARS Virus; Coronavirus; Treatment Outcome; Public-private Sector Partnerships; Quality Indicators

Figure

• 

  Fig. 1 Sputum AFB smear test coverage among pulmonary TB cases, which were initially registered for the third and fourth quarters of 2019 and the first and second quarters of 2020.Sputum AFB smear test coverage was calculated as the number of patients who had sputum smear test performed divided by the number of patients with pulmonary TB. Cohort data from the third and fourth quarters of 2019 and the first and second quarters of 2020 were collected and updated between July 2019 (the third quarter of 2019) and June 2020 (the second quarter of 2020).AFB = acid-fast bacilli, TB = tuberculosis.

• 

  Fig. 2 Sputum AFB culture test coverage among pulmonary TB cases, which were initially registered for the third and fourth quarters of 2019 and the first and second quarters of 2020.Sputum AFB culture test coverage was calculated as the number of patients who had sputum culture test performed divided by the number of patients with pulmonary TB. Cohort data from the third and fourth quarters of 2019 and the first and second quarters of 2020 were collected and updated between July 2019 (the third quarter of 2019) and June 2020 (the second quarter of 2020).AFB = acid-fast bacilli, TB = tuberculosis.

• 

  Fig. 3 Adherence to initial standard anti-TB treatment recommended by the guidelines among TB cases, which were initially registered for the third and fourth quarters of 2019 and the first and second quarters of 2020.Adherence to initial standard anti-TB treatment was calculated as the number of patients treated with initial standard regimens, including H+R+E+Z, H+R+E, H+E+Z+Rfb, or H+E+Rfb, divided by the number of patients eligible for initial standard anti-TB treatment recommended by the guidelines. Patients with isoniazid-resistant TB, RR-TB, and MDR-TB were excluded. Patients whose data regarding anti-TB drugs were not entered in the Korean National TB Surveillance System were excluded. Patients registered as “treatment after failure” were excluded. Cohort data from the third and fourth quarters of 2019 and the first and second quarters of 2020 were collected and updated between July 2019 (the third quarter of 2019) and June 2020 (the second quarter of 2020).TB = tuberculosis, H = isoniazid, R = rifampicin, E = ethambutol, Z = pyrazinamide, Rfb = rifabutin. RR = rifampicina resistant, MDR = multidrug resistant.

• 

  Fig. 4 Drug susceptibility test coverage among culture-confirmed TB cases, which were initially registered for the second, third, and fourth quarters of 2019 and the first quarters of 2020.Drug susceptibility test coverage was calculated as the number of patients with culture-based or molecular drug-susceptible test results divided by the number of patients with culture-confirmed TB cases. Cohort data from the second, third, and fourth quarters of 2019 and the first quarter of 2020 were collected and updated between July 2019 (the third quarter of 2019) and June 2020 (the second quarter of 2020).TB = tuberculosis.

• 

  Fig. 5 Treatment success rate among the smear-positive drug-susceptible pulmonary TB cohort, which were initially registered for the third and fourth quarters of 2018 and the first and second quarters of 2019.Treatment success rate was calculated as the number of smear-positive drug-susceptible pulmonary TB cases that were successfully treated divided by the number of smear-positive drug-susceptible pulmonary TB cases registered as treatment success, treatment failed, loss to follow-up, died, and still on treatment. Smear-positive pulmonary TB cases are defined by ICD-10 codes (A15.00 or A15.01) and positive results of sputum AFB smear tests. Patients with RR-TB and MDR-TB were excluded. Patients who were “transferred out” to another treatment unit, returned to their home country, and died of non-TB-related causes were excluded. Cohort data from the third and fourth quarters of 2018 and the first and second quarters of 2019 were collected and updated between July 2019 (the third quarter of 2019) and June 2020 (the second quarter of 2020).TB = tuberculosis, ICD = International Classification of Diseases, AFB = acid-fast bacilli, RR = rifampicina resistant, MDR = multidrug resistant.

• 

  Fig. 6 Loss to follow-up rate among TB cases, which were initially registered for the third and fourth quarters of 2018 and the first and second quarters of 2019.Loss to follow-up rate was calculated as the number of TB cases that were registered as loss to follow-up divided by the number of TB cases registered as treatment success, treatment failed, loss to follow-up, died, and still on treatment. Patients with RR-TB and MDR-TB were excluded. Patients who were “transferred out” to another treatment unit, returned to their home country, and died due to non-TB-related causes were excluded. Cohort data from the third and fourth quarters of 2018 and the first and second quarters of 2019 were collected and updated between July 2019 (the third quarter of 2019) and June 2020 (the second quarter of 2020).TB = tuberculosis, RR = rifampicina resistant, MDR = multidrug resistant.

Reference

1. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report-51 (11 March 2020). Accessed October 27, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10.

2. Chudasama YV, Gillies CL, Zaccardi F, Coles B, Davies MJ, Seidu S, et al. Impact of COVID-19 on routine care for chronic diseases: a global survey of views from healthcare professionals. Diabetes Metab Syndr. 2020; 14(5):965–967. PMID: 32604016.

3. Alene KA, Wangdi K, Clements ACA. Impact of the COVID-19 pandemic on tuberculosis control: an overview. Trop Med Infect Dis. 2020; 5(3):123.

4. McQuaid CF, McCreesh N, Read JM, Sumner T. CMMID COVID-19 Working Group, Houben RMGJ, et al. The potential impact of COVID-19-related disruption on tuberculosis burden. Eur Respir J. 2020; 56(2):2001718. PMID: 32513784.

5. Oh J, Lee JK, Schwarz D, Ratcliffe HL, Markuns JF, Hirschhorn LR. National response to COVID-19 in the Republic of Korea and lessons learned for other countries. Health Syst Reform. 2020; 6(1):e1753464. PMID: 32347772.

6. Kwak N, Hwang SS, Yim JJ. Effect of COVID-19 on tuberculosis notification, South Korea. Emerg Infect Dis. 2020; 26(10):2506–2508. PMID: 32672531.

7. Min J, Kim HW, Ko Y, Oh JY, Kang JY, Lee J, et al. Tuberculosis surveillance and monitoring under the National Public-Private Mix Tuberculosis Control Project in South Korea 2016-2017. Tuberc Respir Dis (Seoul). 2020; 83(3):218–227. PMID: 32610836.

8. Korea Centers for Disease Control & Prevention. Annual Report on the Notified Tuberculosis in Korea, 2019. Cheongju, Korea: Korea Centers for Disease Control & Prevention;2020.

9. Kang HY, Yoo H, Park W, Go U, Jeong E, Jung KS, et al. Tuberculosis Notification Completeness and Timeliness in the Republic of Korea During 2012-2014. Osong Public Health Res Perspect. 2016; 7(5):320–326. PMID: 27812491.

10. World Health Organization. Definitions and Reporting Framework for Tuberculosis – 2013 Revision. Geneva, Switzerland: World Health Organization;2013.

11. Korea Centers for Disease Control & Prevention. Korean Guidelines for Tuberculosis. 4th ed. Cheongju, Korea: Joint Committee for the Revision of Korean Guidelines for Tuberculosis and Korea Centers for Disease Control & Prevention;2020.

12. Kim M, Park K, Kim Y, Kim Y, Yeom H, Hwang I, et al. Weekly report on the COVID-19 situation in the Republic of Korea (as of July 4, 2020). Public Health Wkly Rep. 2020; 13(28):2032–2046.

13. World Health Organization. COVID-19: considerations for tuberculosis (TB) care. Accessed 24 Aug 2020. https://www.who.int/docs/default-source/documents/tuberculosis/infonote-tb-covid-19.pdf.

14. Magassouba AS, Diallo BD, Camara LM, Sow K, Camara S, Bah B, et al. Impact of the Ebola virus disease outbreak (2014–2016) on tuberculosis surveillance activities by Guinea's National Tuberculosis Control Program: a time series analysis. BMC Public Health. 2020; 20(1):1200. PMID: 32753044.

15. Desta KT, Kessely DB, Daboi JG. Evaluation of the performance of the National Tuberculosis Program of Liberia during the 2014–2015 Ebola outbreak. BMC Public Health. 2019; 19(1):1221. PMID: 31484578.

16. Parpia AS, Ndeffo-Mbah ML, Wenzel NS, Galvani AP. Effects of response to 2014–2015 Ebola outbreak on deaths from Malaria, HIV/AIDS, and tuberculosis, West Africa. Emerg Infect Dis. 2016; 22(3):433–441. PMID: 26886846.

17. Visca D, Tiberi S, Pontali E, Spanevello A, Migliori GB. Tuberculosis in the time of COVID-19: quality of life and digital innovation. Eur Respir J. 2020; 56(2):2001998. PMID: 32513783.